Abstract
Summary
LPI (LP Information)' newest research report, the “Molecular Diagnostics in Point of Care Industry Forecast” looks at past sales and reviews total world Molecular Diagnostics in Point of Care sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Diagnostics in Point of Care sales for 2023 through 2029. With Molecular Diagnostics in Point of Care sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Diagnostics in Point of Care industry.
This Insight Report provides a comprehensive analysis of the global Molecular Diagnostics in Point of Care landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnostics in Point of Care portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnostics in Point of Care market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnostics in Point of Care and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnostics in Point of Care.
The global Molecular Diagnostics in Point of Care market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Molecular Diagnostics in Point of Care players cover Abbott, Accelerate Diagnostics, Ador Diagnostics, Beckman Coulter, Becton, Dickinson and Company, Binx Health, Biocartis, bioMérieux and Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnostics in Point of Care market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Polymerase Chain Reaction
In Situ Hybridization
Gene Chips
Next Generation Sequencing
Segmentation by application
Hospitals and Clinics
Independent Clinical Laboratories
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Accelerate Diagnostics
Ador Diagnostics
Beckman Coulter
Becton, Dickinson and Company
Binx Health
Biocartis
bioMérieux
Bio-Rad Laboratories
Bosch Healthcare Solutions
Curetis
Eurofins Scientific
Genetic Signatures
Grifols
Hibergene Diagnostics
Lumos Diagnostics
Roche
Siemens
Thermo Fisher Scientific
This Insight Report provides a comprehensive analysis of the global Molecular Diagnostics in Point of Care landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnostics in Point of Care portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnostics in Point of Care market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnostics in Point of Care and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnostics in Point of Care.
The global Molecular Diagnostics in Point of Care market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Molecular Diagnostics in Point of Care players cover Abbott, Accelerate Diagnostics, Ador Diagnostics, Beckman Coulter, Becton, Dickinson and Company, Binx Health, Biocartis, bioMérieux and Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnostics in Point of Care market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Polymerase Chain Reaction
In Situ Hybridization
Gene Chips
Next Generation Sequencing
Segmentation by application
Hospitals and Clinics
Independent Clinical Laboratories
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Accelerate Diagnostics
Ador Diagnostics
Beckman Coulter
Becton, Dickinson and Company
Binx Health
Biocartis
bioMérieux
Bio-Rad Laboratories
Bosch Healthcare Solutions
Curetis
Eurofins Scientific
Genetic Signatures
Grifols
Hibergene Diagnostics
Lumos Diagnostics
Roche
Siemens
Thermo Fisher Scientific
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Molecular Diagnostics in Point of Care Market Size 2018-2029
2.1.2 Molecular Diagnostics in Point of Care Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Molecular Diagnostics in Point of Care Segment by Type
2.2.1 Polymerase Chain Reaction
2.2.2 In Situ Hybridization
2.2.3 Gene Chips
2.2.4 Next Generation Sequencing
2.3 Molecular Diagnostics in Point of Care Market Size by Type
2.3.1 Molecular Diagnostics in Point of Care Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Molecular Diagnostics in Point of Care Market Size Market Share by Type (2018-2023)
2.4 Molecular Diagnostics in Point of Care Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Independent Clinical Laboratories
2.5 Molecular Diagnostics in Point of Care Market Size by Application
2.5.1 Molecular Diagnostics in Point of Care Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Molecular Diagnostics in Point of Care Market Size Market Share by Application (2018-2023)
3 Molecular Diagnostics in Point of Care Market Size by Player
3.1 Molecular Diagnostics in Point of Care Market Size Market Share by Players
3.1.1 Global Molecular Diagnostics in Point of Care Revenue by Players (2018-2023)
3.1.2 Global Molecular Diagnostics in Point of Care Revenue Market Share by Players (2018-2023)
3.2 Global Molecular Diagnostics in Point of Care Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Molecular Diagnostics in Point of Care by Regions
4.1 Molecular Diagnostics in Point of Care Market Size by Regions (2018-2023)
4.2 Americas Molecular Diagnostics in Point of Care Market Size Growth (2018-2023)
4.3 APAC Molecular Diagnostics in Point of Care Market Size Growth (2018-2023)
4.4 Europe Molecular Diagnostics in Point of Care Market Size Growth (2018-2023)
4.5 Middle East & Africa Molecular Diagnostics in Point of Care Market Size Growth (2018-2023)
5 Americas
5.1 Americas Molecular Diagnostics in Point of Care Market Size by Country (2018-2023)
5.2 Americas Molecular Diagnostics in Point of Care Market Size by Type (2018-2023)
5.3 Americas Molecular Diagnostics in Point of Care Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Molecular Diagnostics in Point of Care Market Size by Region (2018-2023)
6.2 APAC Molecular Diagnostics in Point of Care Market Size by Type (2018-2023)
6.3 APAC Molecular Diagnostics in Point of Care Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Molecular Diagnostics in Point of Care by Country (2018-2023)
7.2 Europe Molecular Diagnostics in Point of Care Market Size by Type (2018-2023)
7.3 Europe Molecular Diagnostics in Point of Care Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Molecular Diagnostics in Point of Care by Region (2018-2023)
8.2 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Type (2018-2023)
8.3 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Molecular Diagnostics in Point of Care Market Forecast
10.1 Global Molecular Diagnostics in Point of Care Forecast by Regions (2024-2029)
10.1.1 Global Molecular Diagnostics in Point of Care Forecast by Regions (2024-2029)
10.1.2 Americas Molecular Diagnostics in Point of Care Forecast
10.1.3 APAC Molecular Diagnostics in Point of Care Forecast
10.1.4 Europe Molecular Diagnostics in Point of Care Forecast
10.1.5 Middle East & Africa Molecular Diagnostics in Point of Care Forecast
10.2 Americas Molecular Diagnostics in Point of Care Forecast by Country (2024-2029)
10.2.1 United States Molecular Diagnostics in Point of Care Market Forecast
10.2.2 Canada Molecular Diagnostics in Point of Care Market Forecast
10.2.3 Mexico Molecular Diagnostics in Point of Care Market Forecast
10.2.4 Brazil Molecular Diagnostics in Point of Care Market Forecast
10.3 APAC Molecular Diagnostics in Point of Care Forecast by Region (2024-2029)
10.3.1 China Molecular Diagnostics in Point of Care Market Forecast
10.3.2 Japan Molecular Diagnostics in Point of Care Market Forecast
10.3.3 Korea Molecular Diagnostics in Point of Care Market Forecast
10.3.4 Southeast Asia Molecular Diagnostics in Point of Care Market Forecast
10.3.5 India Molecular Diagnostics in Point of Care Market Forecast
10.3.6 Australia Molecular Diagnostics in Point of Care Market Forecast
10.4 Europe Molecular Diagnostics in Point of Care Forecast by Country (2024-2029)
10.4.1 Germany Molecular Diagnostics in Point of Care Market Forecast
10.4.2 France Molecular Diagnostics in Point of Care Market Forecast
10.4.3 UK Molecular Diagnostics in Point of Care Market Forecast
10.4.4 Italy Molecular Diagnostics in Point of Care Market Forecast
10.4.5 Russia Molecular Diagnostics in Point of Care Market Forecast
10.5 Middle East & Africa Molecular Diagnostics in Point of Care Forecast by Region (2024-2029)
10.5.1 Egypt Molecular Diagnostics in Point of Care Market Forecast
10.5.2 South Africa Molecular Diagnostics in Point of Care Market Forecast
10.5.3 Israel Molecular Diagnostics in Point of Care Market Forecast
10.5.4 Turkey Molecular Diagnostics in Point of Care Market Forecast
10.5.5 GCC Countries Molecular Diagnostics in Point of Care Market Forecast
10.6 Global Molecular Diagnostics in Point of Care Forecast by Type (2024-2029)
10.7 Global Molecular Diagnostics in Point of Care Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Abbott
11.1.1 Abbott Company Information
11.1.2 Abbott Molecular Diagnostics in Point of Care Product Offered
11.1.3 Abbott Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Abbott Main Business Overview
11.1.5 Abbott Latest Developments
11.2 Accelerate Diagnostics
11.2.1 Accelerate Diagnostics Company Information
11.2.2 Accelerate Diagnostics Molecular Diagnostics in Point of Care Product Offered
11.2.3 Accelerate Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Accelerate Diagnostics Main Business Overview
11.2.5 Accelerate Diagnostics Latest Developments
11.3 Ador Diagnostics
11.3.1 Ador Diagnostics Company Information
11.3.2 Ador Diagnostics Molecular Diagnostics in Point of Care Product Offered
11.3.3 Ador Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Ador Diagnostics Main Business Overview
11.3.5 Ador Diagnostics Latest Developments
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Information
11.4.2 Beckman Coulter Molecular Diagnostics in Point of Care Product Offered
11.4.3 Beckman Coulter Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Beckman Coulter Main Business Overview
11.4.5 Beckman Coulter Latest Developments
11.5 Becton, Dickinson and Company
11.5.1 Becton, Dickinson and Company Company Information
11.5.2 Becton, Dickinson and Company Molecular Diagnostics in Point of Care Product Offered
11.5.3 Becton, Dickinson and Company Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Becton, Dickinson and Company Main Business Overview
11.5.5 Becton, Dickinson and Company Latest Developments
11.6 Binx Health
11.6.1 Binx Health Company Information
11.6.2 Binx Health Molecular Diagnostics in Point of Care Product Offered
11.6.3 Binx Health Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Binx Health Main Business Overview
11.6.5 Binx Health Latest Developments
11.7 Biocartis
11.7.1 Biocartis Company Information
11.7.2 Biocartis Molecular Diagnostics in Point of Care Product Offered
11.7.3 Biocartis Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Biocartis Main Business Overview
11.7.5 Biocartis Latest Developments
11.8 bioMérieux
11.8.1 bioMérieux Company Information
11.8.2 bioMérieux Molecular Diagnostics in Point of Care Product Offered
11.8.3 bioMérieux Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 bioMérieux Main Business Overview
11.8.5 bioMérieux Latest Developments
11.9 Bio-Rad Laboratories
11.9.1 Bio-Rad Laboratories Company Information
11.9.2 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Product Offered
11.9.3 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Bio-Rad Laboratories Main Business Overview
11.9.5 Bio-Rad Laboratories Latest Developments
11.10 Bosch Healthcare Solutions
11.10.1 Bosch Healthcare Solutions Company Information
11.10.2 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Product Offered
11.10.3 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Bosch Healthcare Solutions Main Business Overview
11.10.5 Bosch Healthcare Solutions Latest Developments
11.11 Curetis
11.11.1 Curetis Company Information
11.11.2 Curetis Molecular Diagnostics in Point of Care Product Offered
11.11.3 Curetis Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Curetis Main Business Overview
11.11.5 Curetis Latest Developments
11.12 Eurofins Scientific
11.12.1 Eurofins Scientific Company Information
11.12.2 Eurofins Scientific Molecular Diagnostics in Point of Care Product Offered
11.12.3 Eurofins Scientific Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Eurofins Scientific Main Business Overview
11.12.5 Eurofins Scientific Latest Developments
11.13 Genetic Signatures
11.13.1 Genetic Signatures Company Information
11.13.2 Genetic Signatures Molecular Diagnostics in Point of Care Product Offered
11.13.3 Genetic Signatures Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Genetic Signatures Main Business Overview
11.13.5 Genetic Signatures Latest Developments
11.14 Grifols
11.14.1 Grifols Company Information
11.14.2 Grifols Molecular Diagnostics in Point of Care Product Offered
11.14.3 Grifols Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Grifols Main Business Overview
11.14.5 Grifols Latest Developments
11.15 Hibergene Diagnostics
11.15.1 Hibergene Diagnostics Company Information
11.15.2 Hibergene Diagnostics Molecular Diagnostics in Point of Care Product Offered
11.15.3 Hibergene Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Hibergene Diagnostics Main Business Overview
11.15.5 Hibergene Diagnostics Latest Developments
11.16 Lumos Diagnostics
11.16.1 Lumos Diagnostics Company Information
11.16.2 Lumos Diagnostics Molecular Diagnostics in Point of Care Product Offered
11.16.3 Lumos Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Lumos Diagnostics Main Business Overview
11.16.5 Lumos Diagnostics Latest Developments
11.17 Roche
11.17.1 Roche Company Information
11.17.2 Roche Molecular Diagnostics in Point of Care Product Offered
11.17.3 Roche Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Roche Main Business Overview
11.17.5 Roche Latest Developments
11.18 Siemens
11.18.1 Siemens Company Information
11.18.2 Siemens Molecular Diagnostics in Point of Care Product Offered
11.18.3 Siemens Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Siemens Main Business Overview
11.18.5 Siemens Latest Developments
11.19 Thermo Fisher Scientific
11.19.1 Thermo Fisher Scientific Company Information
11.19.2 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Product Offered
11.19.3 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Thermo Fisher Scientific Main Business Overview
11.19.5 Thermo Fisher Scientific Latest Developments
12 Research Findings and Conclusion